Coronary artery calcium score as a gatekeeper for further testing in patients with low pretest probability of obstructive coronary artery disease: A cost-effectiveness analysis

被引：4

作者：

Gomes, Daniel A. ^{[1
]}

Lopes, Pedro M. ^{[1
]}

Albuquerque, Francisco ^{[1
]}

Freitas, Pedro ^{[1
,3
]}

Silva, Claudia ^{[1
]}

Guerreiro, Sara ^{[1
]}

Abecasis, Joao ^{[1
]}

Santos, Ana Coutinho ^{[2
,3
]}

Saraiva, Carla ^{[2
]}

Ferreira, Jorge ^{[1
]}

Goncalves, Pedro de Araujo ^{[1
,3
]}

Marques, Hugo ^{[1
,3
]}

Mendes, Miguel ^{[1
]}

Ferreira, Antonio M. ^{[1
,3
]}

机构：

[1] Hosp Santa Cruz, Ctr Hosp Lisboa Ocidental, Dept Cardiol, Lisbon, Portugal

[2] Hosp Santa Cruz, Ctr Hosp Lisboa Ocidental, Dept Radiol, Lisbon, Portugal

[3] Hosp Luz, UNICA Cardiovasc CT & MR Unit, Lisbon, Portugal

来源：

REVISTA PORTUGUESA DE CARDIOLOGIA | 2023年 / 42卷 / 07期

关键词：

Cost-effectiveness; Coronary artery disease; Diagnosis; Coronary artery calcium score; Coronary CT angiography; COMPUTED-TOMOGRAPHY; ANGIOGRAPHY; LIKELIHOOD; DIAGNOSIS; SOCIETY;

D O I：

10.1016/j.repc.2023.03.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction and objectives: Current guidelines recommend not routinely testing patients with chest pain and low pretest probability (PTP <15%) of obstructive coronary artery disease (CAD), but envisage the use of risk modifiers, such as coronary artery calcium score (CACS), to refine patient selection for testing. We aimed to assess the cost-effectiveness (CE) of three different testing strategies in this population: (A) defer testing; (B) perform CACS, withholding further testing if CACS=0, and proceeding to coronary CT angiography (CCTA) if CACS>0; (C) CCTA in all. Methods: We developed a CE model using data from a two-center cross-sectional study of 1385 patients with non-acute chest pain and PTP <15% undergoing CACS followed by CCTA. Key input data included the prevalence of obstructive CAD on CCTA (10.3%), the proportion with CACS=0 (57%), and the negative predictive value of CACS for obstructive CAD on CCTA (98.1%). Results: Not testing would correctly classify 89.7% of cases and at a cost of euro 121 433 per 1000 patients. Using CACS as a gatekeeper for CCTA would correctly diagnose 98.9% of cases and cost euro 247 116/1000 patients. Employing first-line CCTA would correctly classify all patients, at a cost of euro 271 007/1000 diagnosed patients. The added cost for an additional correct diagnosis was euro 1366 for CACS & PLUSMN;CCTA vs. no testing, and euro 2172 for CCTA vs. CACS & PLUSMN;CCTA. Conclusions: CACS as a gatekeeper for further testing is cost-effective between a threshold of euro 1366 and euro 2172 per additional correct diagnosis. CCTA yields the most correct diagnoses and is cost-effective above a threshold of euro 2172. & COPY; 2023 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espan & SIM;a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

引用

页码：617 / 624

页数：8

共 31 条

[31] Incorporating Coronary Calcification Into Pre-Test Assessment of the Likelihood of Coronary Artery Disease [J].

Winther, Simon ;

Schmidt, Samuel Emil ;

Mayrhofer, Thomas ;

Botker, Hans Erik ;

Hoffmann, Udo ;

Douglas, Pamela S. ;

Wijns, William ;

Bax, Jeroen ;

Nissen, Louise ;

Lynggaard, Vibeke ;

Christiansen, Jens Juel ;

Saraste, Antti ;

Bottcher, Morten ;

Knuuti, Juhani .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (21) :2421-2432

← 1 2 3 4 →